These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21082239)

  • 1. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
    Kondo M; Hoshi SL; Yamanaka T; Ishiguro H; Toi M
    Breast Cancer Res Treat; 2011 Jun; 127(3):739-49. PubMed ID: 21082239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.
    Kondo M; Hoshi SL; Ishiguro H; Toi M
    Breast Cancer Res Treat; 2012 Jun; 133(2):759-68. PubMed ID: 22315134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan.
    Kondo M; Hoshi SL; Ishiguro H; Yoshibayashi H; Toi M
    Breast Cancer Res Treat; 2008 Nov; 112(1):175-87. PubMed ID: 18075786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.
    Vanderlaan BF; Broder MS; Chang EY; Oratz R; Bentley TG
    Am J Manag Care; 2011; 17(7):455-64. PubMed ID: 21819166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
    Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US insurance program's experience with a multigene assay for early-stage breast cancer.
    Hornberger J; Chien R; Krebs K; Hochheiser L
    Am J Manag Care; 2011 May; 17(5 Spec No):e194-202. PubMed ID: 21711071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
    Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
    Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
    Hornberger J; Cosler LE; Lyman GH
    Am J Manag Care; 2005 May; 11(5):313-24. PubMed ID: 15898220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
    Hall PS; McCabe C; Stein RC; Cameron D
    J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
    Lamond NW; Skedgel C; Rayson D; Lethbridge L; Younis T
    Breast Cancer Res Treat; 2012 Jun; 133(3):1115-23. PubMed ID: 22361999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
    Orr RK; Col NF; Kuntz KM
    Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
    El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
    Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
    Yang JJ; Park SK; Cho LY; Han W; Park B; Kim H; Lee KS; Hahn SK; Cho SI; Ahn SH; Noh DY;
    Clin Ther; 2010 Jun; 32(6):1122-38. PubMed ID: 20637966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.